Transcenta Announces First Patient Dosed In Phase Iia Study Of Claudin18.2 Monoclonal Antibody Tst001 Combined With Cisplatin And Gemcitabine For The First Line Treatment Of Biliary Tract Cancer
Transcenta Holding Limited A Clinical Stage Biopharmaceutical Company With Fully-Integrated Capabilities In Discovery, Research, Development And Manufacturing Of Antibody-Based Therapeutics, Announces The Successful Dosing Of First Patient In China Phase Iia Study Of Tst001, A Claudin18.2 Monoclonal Antibody, Combined With Cisplatin And Gemcitabine For The First Line Treatment Of Systemic Treatment-Na
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
